Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Concert Pharmaceuticals
Age
18–60
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy, adult, male or female, aged 18-60
Non-smoker who has not used nicotine-containing products for at least 3 months prior to the first dosing
Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at screening
If of reproductive age, willing and able to use a medically highly effective form of birth control 4 weeks prior to first dose, during the study and for 30 days following last dose of study medication
Capable of giving informed consent and complying with study procedures
You may not be if
History or presence of clinically significant medical or psychiatric condition or disease
History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing
Presence or history of significant gastrointestinal, liver or kidney disease, or any other condition that is known to interfere with drug absorption, distribution, metabolism or excretion, or known to potentiate or predispose to undesired effects
History of prolonged QT syndrome or a QTc interval with Fridericia's correction (QTcF) \> 450 msec for males or QTcF \> 470 msec for females at screening visit or prior to the first dosing
Abnormal liver function at screening
Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study drug
Positive results for coronavirus infection (COVID-19) at screening or check-in
Positive drug or alcohol results at screening or check-in
Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV)
Participation in another clinical study within 30 days prior to, and 30 days after the first dosing.
Clareo Health | Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects
